Compare BLZE & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLZE | RCEL |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.6M | 102.5M |
| IPO Year | 2021 | N/A |
| Metric | BLZE | RCEL |
|---|---|---|
| Price | $5.14 | $3.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $9.50 | $8.67 |
| AVG Volume (30 Days) | ★ 778.3K | 197.9K |
| Earning Date | 02-24-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $141,859,000.00 | $72,401,000.00 |
| Revenue This Year | $16.40 | $13.12 |
| Revenue Next Year | $11.07 | $27.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 15.73 | ★ 20.59 |
| 52 Week Low | $3.94 | $3.25 |
| 52 Week High | $10.86 | $14.16 |
| Indicator | BLZE | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 52.65 | 41.28 |
| Support Level | $4.63 | $3.36 |
| Resistance Level | $4.92 | $3.61 |
| Average True Range (ATR) | 0.19 | 0.18 |
| MACD | 0.12 | 0.03 |
| Stochastic Oscillator | 99.30 | 34.78 |
Backblaze Inc provides cloud storage services. The company offers services such as Backblaze B2 Cloud Storage, which enables customers to store data, developers to build applications, and partners to expand their use cases. It is offered as a consumption-based Infrastructure-as-a-Service (IaaS) and serves use cases including backups, multi-cloud, application development, and ransomware protection and Backblaze Computer Backup automatically backs up data from laptops and desktops for businesses and individuals. Geographically, it derives a majority of revenue from the United States and the rest from the United Kingdom, Canada, and Other regions.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.